ID   FLO-1
AC   CVCL_2045
SY   Flo-1; Flo 1; FLO1; FLO
DR   BTO; BTO_0003641
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 880
DR   BioSample; SAMN03473447
DR   cancercelllines; CVCL_2045
DR   Cell_Model_Passport; SIDM01041
DR   Cosmic; 1599339
DR   Cosmic-CLP; 1503361
DR   DepMap; ACH-001500
DR   DSMZ; ACC-698
DR   DSMZCellDive; ACC-698
DR   ECACC; 11012001
DR   EGA; EGAS00001000978
DR   GDSC; 1503361
DR   GEO; GSM1669793
DR   IARC_TP53; 21628
DR   PharmacoDB; FLO1_367_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54834992
RX   PubMed=9407969;
RX   PubMed=10078940;
RX   PubMed=20075370;
RX   PubMed=23795680;
RX   PubMed=27397505;
RX   PubMed=27594985;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: ~40-50 hours (DSMZ=ACC-698).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys277Phe (c.830G>T); ClinVar=VCV000458567; Zygosity=Homozygous (PubMed=20075370; Cosmic-CLP=1503361; DepMap=ACH-001500).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Genomics; Whole genome sequencing.
CC   Omics: Phenotyping; CRISPR screening.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; Microarray.
CC   Genome ancestry: African=0.63%; Native American=0.21%; East Asian, North=0%; East Asian, South=0.68%; South Asian=0.12%; European, North=71.2%; European, South=27.15% (PubMed=30894373).
CC   Derived from site: In situ; Esophagus; UBERON=UBERON_0001043.
ST   Source(s): Cosmic-CLP=1503361; DepMap=ACH-001500; DSMZ=ACC-698; ECACC=11012001; PubMed=20075370
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11
ST   D16S539: 12,13
ST   D18S51: 14,16
ST   D19S433: 16
ST   D21S11: 30,32.2
ST   D2S1338: 17,24
ST   D3S1358: 15
ST   D5S818: 12,14
ST   D7S820: 8
ST   D8S1179: 13
ST   FGA: 21
ST   Penta D: 11,12
ST   Penta E: 5,17
ST   TH01: 6
ST   TPOX: 9,11
ST   vWA: 16
DI   NCIt; C7027; Barrett adenocarcinoma
DI   ORDO; Orphanet_99976; Adenocarcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   68Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 34
//
RX   PubMed=9407969;
RA   Hughes S.J., Nambu Y., Soldes O.S., Hamstra D., Rehemtulla A.,
RA   Iannettoni M.D., Orringer M.B., Beer D.G.;
RT   "Fas/APO-1 (CD95) is not translocated to the cell membrane in
RT   esophageal adenocarcinoma.";
RL   Cancer Res. 57:5571-5578(1997).
//
RX   PubMed=10078940; DOI=10.1002/(SICI)1098-2744(199902)24:2<128::AID-MC7>3.0.CO;2-F;
RA   Compton K.R., Orringer M.B., Beer D.G.;
RT   "Induction of glutathione s-transferase-pi in Barrett's metaplasia and
RT   Barrett's adenocarcinoma cell lines.";
RL   Mol. Carcinog. 24:128-136(1999).
//
RX   PubMed=20075370; DOI=10.1093/jnci/djp499; PMCID=PMC2902814;
RA   Boonstra J.J., van Marion R., Beer D.G., Lin L., Chaves P.,
RA   Ribeiro C., Pereira A.D., Roque L., Darnton S.J., Altorki N.K.,
RA   Schrump D.S., Klimstra D.S., Tang L.H., Eshleman J.R., Alvarez H.,
RA   Shimada Y., van Dekken H., Tilanus H.W., Dinjens W.N.M.;
RT   "Verification and unmasking of widely used human esophageal
RT   adenocarcinoma cell lines.";
RL   J. Natl. Cancer Inst. 102:271-274(2010).
//
RX   PubMed=23795680; DOI=10.1111/dote.12095;
RA   Boonstra J.J., Tilanus H.W., Dinjens W.N.M.;
RT   "Translational research on esophageal adenocarcinoma: from cell line
RT   to clinic.";
RL   Dis. Esophagus 28:90-96(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27594985; DOI=10.12688/f1000research.7033.1; PMCID=PMC4991527;
RA   Contino G., Eldridge M.D., Secrier M., Bower L., Elliott R.F., Weaver J.,
RA   Lynch A.G., Edwards P.A.W., Fitzgerald R.C.;
RT   "Whole-genome sequencing of nine esophageal adenocarcinoma cell lines.";
RL   F1000Research 5:1336.1-1336.12(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//